Table 1 Clinicopathological factors and expressions of the MEX3 family genes in HCC.
From: Comprehensive bioinformatics analysis of MEX3 family genes in hepatocellular carcinoma
Characteristics | MEX3A | P | MEX3B | P | MEX3C | P | MEX3D | P | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Low expression | High expression | Low expression | High expression | Low expression | High expression | Low expression | High expression | |||||
n | 187 | 187 | 187 | 187 | 187 | 187 | 187 | 187 | ||||
Age, n (%) | 0.0866 | 0.000102 | 0.00825 | 0.132 | ||||||||
< = 60 | 80 (21.4%) | 97 (26%) | 70 (18.8%) | 107 (28.7%) | 76 (20.4%) | 101 (27.1%) | 81 (21.7%) | 96 (25.7%) | ||||
> 60 | 106 (28.4%) | 90 (24.1%) | 117 (31.4%) | 79 (21.2%) | 111 (29.8%) | 85 (22.8%) | 105 (28.2%) | 91 (24.4%) | ||||
BMI, n (%) | 0.000233 | 0.77 | 0.239 | 0.0545 | ||||||||
< = 25 | 74 (22%) | 103 (30.6%) | 89 (26.4%) | 88 (26.1%) | 86 (25.5%) | 91 (27%) | 81 (24%) | 96 (28.5%) | ||||
> 25 | 99 (29.4%) | 61 (18.1%) | 83 (24.6%) | 77 (22.8%) | 88 (26.1%) | 72 (21.4%) | 90 (26.7%) | 70 (20.8%) | ||||
Gender, n (%) | 0.224 | 0.00572 | 0.00572 | 0.740 | ||||||||
Female | 55 (14.7%) | 66 (17.6%) | 48 (12.8%) | 73 (19.5%) | 48 (12.8%) | 73 (19.5%) | 59 (15.8%) | 62 (16.6%) | ||||
Male | 132 (35.3%) | 121 (32.4%) | 139 (37.2%) | 114 (30.5%) | 139 (37.2%) | 114 (30.5%) | 128 (34.2%) | 125 (33.4%) | ||||
Race, n (%) | 0.000341 | 0.53 | 0.349 | 0.456 | ||||||||
Asian & Black or African American | 70 (19.3%) | 107 (29.6%) | 86 (23.8%) | 91 (25.1%) | 91 (25.1%) | 86 (23.8%) | 83 (22.9%) | 94 (26%) | ||||
White | 108 (29.8%) | 77 (21.3%) | 96 (26.5%) | 89 (24.6%) | 86 (23.8%) | 99 (27.3%) | 94 (26%) | 91 (25.1%) | ||||
Pathologic T stage, n (%) | 0.426 | 0.18 | 0.00914 | 0.00195 | ||||||||
T1 | 98 (26.4%) | 85 (22.9%) | 98 (26.4%) | 85 (22.9%) | 102 (27.5%) | 81 (21.8%) | 107 (28.8%) | 76 (20.5%) | ||||
T2 | 44 (11.9%) | 51 (13.7%) | 49 (13.2%) | 46 (12.4%) | 50 (13.5%) | 45 (12.1%) | 44 (11.9%) | 51 (13.7%) | ||||
T3&T4 | 44 (11.9%) | 49 (13.2%) | 39 (10.5%) | 54 (14.6%) | 34 (9.2%) | 59 (15.9%) | 34 (9.2%) | 59 (15.9%) | ||||
Pathologic stage, n (%) | 0.627 | 0.0977 | 0.0109 | 0.00275 | ||||||||
Stage I | 92 (26.3%) | 81 (23.1%) | 93 (26.6%) | 80 (22.9%) | 97 (27.7%) | 76 (21.7%) | 102 (29.1%) | 71 (20.3%) | ||||
Stage II | 42 (12%) | 45 (12.9%) | 48 (13.7%) | 39 (11.1%) | 49 (14%) | 38 (10.9%) | 44 (12.6%) | 43 (12.3%) | ||||
Stage III & Stage IV | 43 (12.3%) | 47 (13.4%) | 37 (10.6%) | 53 (15.1%) | 34 (9.7%) | 56 (16%) | 33 (9.4%) | 57 (16.3%) | ||||
Tumor status, n (%) | 0.142 | 0.738 | 0.0373 | 0.0577 | ||||||||
Tumor free | 107 (30.1%) | 95 (26.8%) | 102 (28.7%) | 100 (28.2%) | 111 (31.3%) | 91 (25.6%) | 109 (30.7%) | 93 (26.2%) | ||||
With tumor | 69 (19.4%) | 84 (23.7%) | 80 (22.5%) | 73 (20.6%) | 67 (18.9%) | 86 (24.2%) | 67 (18.9%) | 86 (24.2%) | ||||
Histologic grade, n (%) | 0.000339 | 0.0105 | 0.101 | 0.119 | ||||||||
G1 | 36 (9.8%) | 19 (5.1%) | 35 (9.5%) | 20 (5.4%) | 34 (9.2%) | 21 (5.7%) | 30 (8.1%) | 25 (6.8%) | ||||
G2 | 99 (26.8%) | 79 (21.4%) | 95 (25.7%) | 83 (22.5%) | 91 (24.7%) | 87 (23.6%) | 97 (26.3%) | 81 (22%) | ||||
G3&G4 | 51 (13.8%) | 85 (23%) | 56 (15.2%) | 80 (21.7%) | 61 (16.5%) | 75 (20.3%) | 59 (16%) | 77 (20.9%) | ||||
AFP(ng/ml), n (%) | 0.00000121 | 0.0434 | 0.0000875 | 0.0313 | ||||||||
< = 400 | 130 (46.4%) | 85 (30.4%) | 120 (42.9%) | 95 (33.9%) | 129 (46.1%) | 86 (30.7%) | 122 (43.6%) | 93 (33.2%) | ||||
> 400 | 17 (6.1%) | 48 (17.1%) | 27 (9.6%) | 38 (13.6%) | 21 (7.5%) | 44 (15.7%) | 27 (9.6%) | 38 (13.6%) | ||||
Albumin(g/dl), n (%) | 0.136 | 0.275 | 0.37 | 0.106 | ||||||||
< 3.5 | 42 (14%) | 27 (9%) | 41 (13.7%) | 28 (9.3%) | 34 (11.3%) | 35 (11.7%) | 42 (14%) | 27 (9%) | ||||
> = 3.5 | 117 (39%) | 114 (38%) | 120 (40%) | 111 (37%) | 128 (42.7%) | 103 (34.3%) | 115 (38.3%) | 116 (38.7%) | ||||
Prothrombin time, n (%) | 0.248 | 0.394 | 0.658 | 0.518 | ||||||||
< = 4 | 104 (35%) | 104 (35%) | 108 (36.4%) | 100 (33.7%) | 111 (37.4%) | 97 (32.7%) | 106 (35.7%) | 102 (34.3%) | ||||
> 4 | 51 (17.2%) | 38 (12.8%) | 51 (17.2%) | 38 (12.8%) | 45 (15.2%) | 44 (14.8%) | 49 (16.5%) | 40 (13.5%) | ||||
Child–Pugh grade, n (%) | 0.608 | 0.888 | 0.35 | 0.357 | ||||||||
A | 122 (50.6%) | 97 (40.2%) | 126 (52.3%) | 93 (38.6%) | 132 (54.8%) | 87 (36.1%) | 122 (50.6%) | 97 (40.2%) | ||||
B&C | 11 (4.6%) | 11 (4.6%) | 13 (5.4%) | 9 (3.7%) | 11 (4.6%) | 11 (4.6%) | 10 (4.1%) | 12 (5%) | ||||
Vascular invasion, n (%) | 0.408 | 0.526 | 0.611 | 0.130 | ||||||||
No | 116 (36.5%) | 92 (28.9%) | 108 (34%) | 100 (31.4%) | 114 (35.8%) | 94 (29.6%) | 115 (36.2%) | 93 (29.2%) | ||||
Yes | 56 (17.6%) | 54 (17%) | 53 (16.7%) | 57 (17.9%) | 57 (17.9%) | 53 (16.7%) | 51 (16%) | 59 (18.6%) | ||||
Adjacent hepatic tissue inflammation, n (%) | 0.324 | 0.650 | 0.470 | 0.950 | ||||||||
None | 69 (29.1%) | 49 (20.7%) | 58 (24.5%) | 60 (25.3%) | 67 (28.3%) | 51 (21.5%) | 61 (25.7%) | 57 (24.1%) | ||||
Mild & severe | 62 (26.2%) | 57 (24.1%) | 62 (26.2%) | 57 (24.1%) | 62 (26.2%) | 57 (24.1%) | 62 (26.2%) | 57 (24.1%) | ||||
